Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)
Duke University Medical Center, Durham (United States of America)
14
presentations
0
follower
13
more
presentations
in this session
Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial
Speaker:
Associate Professor C. DeFilippi (Baltimore, US)
Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.